Back to Authors

Olsen, Gerilyn M.

https://orcid.org/0009-0009-4843-6042

Mayo Clinic

Medical College of Wisconsin

Citations 3

Characteristics and Outcomes of Infantile Hemangioma With Non, Poor, and Partial Response to Standard-Dose Systemic Beta-Blocker Therapy
Afarideh, Mohsen , Baisi, Katinna E. Rodriguez , Aghazadeh, Nessa , Morel, Kimberly D. , Olsen, Gerilyn M. , Adams, Denise M. , Nopper, Amy J., Garzón, Maria C. , Horii, Kimberly A., Lauren, Christine T. , Mathes, Erin F., McCuaïg, Catherine , Newell, Brandon , Powell, Julie, Shah, Sonal D. , Tollefson, Megha M. , Aghazadeh Mohandesi, Nessa , Baselga, Eulàlia , Frieden, Ilona J. , Powell, Julie

Journal of Vascular Anomalies | April 25, 2025 | Volume: 6 | Issue: 2 | Pages: e112

10.1097/jova.0000000000000112 Get It

Objectives: Systemic beta-blockers are highly effective for the management of infantile hemangiomas (IH), but little is known about infants who do not adequately respond. We aimed to describe the characteristics and outcomes of suboptimal responders to standard-dose systemic beta-blockers in infants with IH. Methods: This is a multicenter retrospective cohort study to evaluate demographics, IH lesion characteristics, and treatment specifics of infants with IH with suboptimal response to baseline standard-dose propranolol treatment. Clinical response was used to assess the outcome after a therapeutic change. Results: Twenty-five infants were included in this study. Seven (28%) had segmental IH, 16 (64%) focal, and 2 (8%) indeterminate. The IHs were located on the head and neck in 21 (84%) infants, with 24 (96%) having a deep or combined component. Therapy changes after standard-dose propranolol treatment failure, most commonly by escalating propranolol dose to ≥2.5 mg/kg/d (59%) or surgical interventions (29%), were associated with good therapeutic effects. Conclusion: Among suboptimal responders to standard-dose systemic propranolol, IHs with a deep or combined component and located on the head and neck were the most common. This retrospective study was largely descriptive in nature with additional exploratory analyses. However, it is still encouraging that for patients with a suboptimal clinical response, higher propranolol doses of ≥2.5–3 mg/kg/d or second-line treatments with surgical interventions or systemic steroids can be considered as potentially safe and effective alternatives. Level of evidence: Level 4 (case series).
Plexiform neurofibroma masquerading as a giant congenital melanocytic nevus
Olsen, Gerilyn M. , Siegel, Dawn H. , Sokumbi, Olayemi , Chiu, Yvonne E , Sokumbi, Olayemi , Chiu, Yvonne E.

Pediatric Dermatology | April 2, 2024 | Volume: 41 | Issue: 5 | Pages: 878-880

10.1111/pde.15611 Get It

AbstractA 4‐month‐old male presented for a large, hypertrichotic brown patch on the upper back with several scattered 0.5–1.5 cm, round to oval, brown macules and patches on the trunk and extremities. The lesion was initially diagnosed as a giant congenital melanocytic nevus based on clinical exam and histopathology with immunohistochemical stains. The patient was later diagnosed with neurofibromatosis type 1, and the lesion on the back developed a “bag of worms” texture consistent with a plexiform neurofibroma and found to harbor a pathogenic variant in the NF1 gene. This case highlights the diagnostic challenge of differentiating these lesions and their overlapping clinical and histopathological features.